KALA BIO, Inc. (NASDAQ:KALA) Sees Significant Increase in Short Interest

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 29,900 shares, an increase of 38.4% from the September 15th total of 21,600 shares. Based on an average daily volume of 19,600 shares, the short-interest ratio is presently 1.5 days. Currently, 0.8% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a report on Monday, August 19th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP bought a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises approximately 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent reporting period. Institutional investors and hedge funds own 24.61% of the company’s stock.

KALA BIO Trading Down 1.9 %

KALA stock opened at $5.17 on Tuesday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.07 and a quick ratio of 3.07. KALA BIO has a 1-year low of $4.21 and a 1-year high of $10.97. The business has a 50 day simple moving average of $5.78 and a two-hundred day simple moving average of $6.38. The company has a market capitalization of $14.56 million, a price-to-earnings ratio of -0.34 and a beta of -2.12.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, August 6th. The company reported ($3.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.40) by $1.24. Research analysts anticipate that KALA BIO will post -11.76 EPS for the current fiscal year.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.